Open Access

Erratum to: A retrospective study to identify risk factors for somnolence and dizziness in patients treated with pregabalin

  • Hiroshi Kato1, 2Email author,
  • Masayuki Miyazaki1, 2,
  • Mio Takeuchi2,
  • Hiroaki Tsukuura3,
  • Mihoko Sugishita3,
  • Yukihiro Noda1, 2 and
  • Kiyofumi Yamada1
Journal of Pharmaceutical Health Care and Sciences20162:5

DOI: 10.1186/s40780-016-0039-6

Received: 11 February 2016

Accepted: 11 February 2016

Published: 17 February 2016

The original article was published in Journal of Pharmaceutical Health Care and Sciences 2015 1:22

Erratum

Unfortunately, after publication of the original version of this article [1], it was noticed that some author corrections were not included in the final article.
  • Within the “Methods” section, the Cockcroft-Gault equation should read as follows:
    • $$ \mathrm{CLcr}\ \left(\mathrm{mL}/ \min \right) = \left(\mathbf{140} - \mathrm{age}\right) \times \mathrm{weight}\ \left(\mathrm{kg}\right)\ /\ \left\{\mathbf{72} \times \mathrm{serum}\ \mathrm{creatinine}\ \left(\mathrm{mg}/\mathrm{dL}\right)\right\} \times \mathbf{0.85}\ \left(\mathrm{if}\ \mathrm{female}\right) $$
  • In addition Table 1 contained some formatting errors. The correct version of Table 1 is included below.
    Table 1

    Patient characteristics (n = 204)

    Age

     Median, year

    61

     Range, year

    18-92

    Gender

     Male, n(%)

    123 (60.3)

     Female , n(%)

    81 (39.7)

    Median CLcra, mL/min

    88.7

    NPb origin

     Cancer related NP, n(%)

    55 (27.0)

     Chemotherapy related NP, n(%)

    24 (11.7)

     Non-cancer related NP, n(%)

    125 (61.3)

    Regular strong opioid

     yes, n(%)

    36 (17.6)

      -fentanyl, n

    17

      -oxycodone, n

    16

      -morphine, n

    3

      Median dosec (range), mg/day

    60 (15–300)

     no, n(%)

    168 (82.4)

    Initial dose of pregabalin

     150 mg/day, n(%)

    124 (60.8)

     75 mg/day, n(%)

    73 (35.8)

     50 mg/day, n(%)

    3 (1.5)

     25 mg/day, n(%)

    4 (1.9)

    aCLcr: creatinine clearance using the Cockcroft-Gault equation

    bNP: neuropathic pain

    cconverted to oral morphine

Notes

Declarations

Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.

Authors’ Affiliations

(1)
Department of Neuropsychopharmacology and Hospital Pharmacy, Nagoya University Graduate School of Medicine
(2)
Division of Clinical Sciences and Neuropsychopharmacology, Meijo University Faculty of Pharmacy
(3)
Department of Clinical Oncology and Chemotherapy, Nagoya University Hospital

References

  1. Kato H, Miyazaki M, Takeuchi M, Tsukuura H, Sugishita M, Noda Y, et al. A retrospective study to identify risk factors for somnolence and dizziness in patients treated with pregabalin. J Pharm Health Care Sci. 2015;1:22. doi:10.1186/s40780-015-0022-7.PubMed CentralView ArticlePubMedGoogle Scholar

Copyright

© Kato et al. 2016

Advertisement